Prostate Cancer

Prostate cancer is the second-leading cause of cancer deaths and the second-most-common cancer in men. The American Cancer Society estimates the disease will strike more than 190,000 men this year and cause more than 33,000 deaths. But doctors say many lives can be saved with annual screenings. Sound familiar? There is similar information shared every October for breast cancer awareness. “It's the men’s equivalent of breast cancer in women – the caveat being: It’s not as lethal as breast cancer,” said Dr. Gideon Lorber, a UPMC urologist who sees patients at UPMC Somerset. “It is definitely something that we would like to screen for,” he said. Dr. Gideon Lorber SUBMITTED PHOTO The prostate is walnut-sized a gland that produces some of the fluid that carries sperm. Located below a man’s bladder, it surrounds the urethra, the tube through which urine passes out of the body. Screening for prostate cancer begins with a simple blood test to check levels of prostate

Al Roker Says He's 'Back Home' Following Prostate Cancer Surgery | PEOPLE.com Skip to content Top Navigation Close Explore PEOPLE.com Profile Menu Follow us Close Share options Close View image Al Roker Says He's 'Back Home' Following Prostate Cancer Surgery: 'See You All Soon' this link is to an external site that may or may not meet accessibility guidelines.

New Cars Used Cars of Search Cars Powered by Cars.com

There are several life-prolonging treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), but there isn’t a lot of information about patient experiences with these treatments. For a recent study, researchers interviewed patients to glean their perspectives on and experiences with life-prolonging treatments. “Given the severity of mCRPC, it is important to consider the possible negative effects of specific treatments on the patients’ [health-related quality of life] and weigh these against the desired positive effects,” the study authors explained. “Still, it has been shown that men with mCRPC lack enough information about the treatments and their possible impact of them on their life.” Sixteen men with mCRPC who were initiating (n=3), were undergoing (n=9), or just finished their first life-prolonging treatment (n=4) of either chemotherapy (Docetaxel, n=11) or hormone-regulating therapy (Abiraterone acetate, n=1; Enzalutamide, n=4) were intervi

MARQUETTE, Mich. (UPHS) - UP Health System – Marquette joins in recognizing Men’s Health Awareness Month this November, also known as “Movember.” UP Health System – Marquette is urging men to take charge of their prostate health this month and throughout the year. Prostate cancer is the most common cancer in American men, with more than 183,000 new cases diagnosed each year, according to the Centers for Disease Control (CDC). When it comes to men’s health, screening for prostate cancer regularly should be a top priority. Detect Disease Early with Regular Check-ups and Exams According to research from the CDC, women are more likely than men to visit the doctor for annual exams and preventive services. Regular check-ups with a primary care physician could help flag issues – even those that are not as obvious – before they become a real problem. Prostate cancer can be detected early through regular screenings. This is particularly important for more at-risk populations, such as men

Researchers have identified a genetic signature in localized prostate cancer that can predict whether the cancer is likely to spread, or metastasize, early in the course of the disease and whether it will respond to anti-androgen therapy, a common treatment for advanced disease. The new gene signature may also be useful for evaluating responses to treatment and for developing new therapies to prevent or treat advanced prostate cancer. “If we could know in advance which patients will develop metastases, we could start treatments earlier and treat the cancer more aggressively,” says the study’s senior author, Cory Abate-Shen, PhD, chair of the Department of Molecular Pharmacology and Therapeutics, the Michael and Stella Chernow Professor of Urologic Sciences (in Urology), and professor of pathology & cell biology (in the Herbert Irving Comprehensive Cancer Center) at Columbia University Vagelos College of Physicians and Surgeons. “Conversely, patients whose disease is likely to re

Prostate cancer is a type of cancer that develops into male reproductive system. Prostate cancer begins when normal cells in the prostate gland start multiplying uncontrollably. It is more prevalent in geriatric men over the age of 65 years. Risk factors for development of prostate cancer are family history, race, and old age. It can be treated by radiation therapy, surgery, chemotherapy, biological therapy, and hormone therapy. The treatment for prostate cancer can be decided on the basis of the stage of cancer. The healthcare professionals such as radiation oncologists and urologists treat prostate cancer. The global prostate cancer treatment market size was valued at $6,887 million in 2018, and is projected to reach $9,904 million by 2026, growing at a CAGR of 4.6% from 2019 to 2026. Download Free Report Sample @ https://ift.tt/37hUVcV The prostate cancer treatment market is expected to experience significant growth during the forecast period, owing to rise in prevalence of pro

Steve Dorfman   | Palm Beach Post While the world was watching battleground states tally their votes, you may have missed the news that longtime Today show weatherman Al Roker disclosed he’d been diagnosed with prostate cancer and would be undergoing surgery. During the Today episode that aired on the Friday after Election Day, Roker, 66, explained, “It's a good news-bad news kind of thing. "Good news is we caught it early. Not great news is that it's a little aggressive, so I'm going to be taking some time off to take care of this." By “catching it early” — in other words, before the tumor’s growth had spread beyond the prostate — Roker and his doctors are confident that he’ll be able to recover from the disease relatively quickly. However, the aggressiveness — that is, the speed of the tumor’s growth — is why, Roker surgeon, Dr. Vincent Laudone, noted “we wanted to treat it, and after discussion regarding all of the different options — surgery, radiation,

November 11, 2020 2 min read Source/Disclosures Disclosures: Tewari reports no relevant financial disclosures. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio A novel “hood technique” for robotic prostatectomy allowed men with prostate cancer to achieve early return of urinary continence without compromising positive surgical margins, according to study results published in European Urology . “The limitations of the existing approach and treatment for prostate cancer is urinary continence and sexual function. Despite treatment, prostate cancer may still come back,” Ash Te

From this CPD module you will learn: The risk factors and prevalence of prostate cancer The presentation of symptoms in prostate cancer How prostate cancer is diagnosed Available treatment options for different stages of prostate cancer Download a printable PDF of this module – including the five-minute test – here.  Take the exam The prostate is a walnut-sized gland that sits under the bladder and around the urethra. Its functions include producing a thick white fluid that mixes with sperm from the testicles to create semen, and contracting its muscles during sexual intercourse to propel the semen into the urethra for ejaculation.(1) The prostate is only found in men, transgender women (the prostate is usually conserved after surgery), non-binary people

"Movember" (held in November) marks a month-long campaign to raise awareness for men’s health issues such as prostate cancer, testicular cancer, and mental health. In Singapore, prostate cancer ranks as the third most common cancer affecting men (according to statistics from the Singapore Cancer Society). Symptoms of prostate cancer The most common symptoms of prostate cancer include: Weak or interrupted flow of urine Frequent urination (especially at night) Difficulty urinating Pain or burning during urination Blood in the urine or semen Nagging pain in the back, hips, or pelvis Painful ejaculation Elevated levels of prostate specific antigen (PSA) “However, the same symptoms may also occur in men with benign prostate hypertrophy (BPH) also known as prostate gland enlargement. Therefore, it is important to seek the advice of your doctor whether additional testing is required when such symptoms arise,” explains Clinical Assistant Profess

For many of us, the year 2020 has been incredibly stressful. It's just one thing after another trying to knock us down. "Today" co-host and weatherman Al Roker is a perfect example. Besides having to cover a record-breaking Atlantic hurricane season (with 28 named storms, five of them major hurricanes), he announced in August that he would be undergoing shoulder replacement surgery, as we wrote about at the time. And now, this past week, Roker revealed that he will be undergoing surgery again -- this time to treat prostate cancer. As he told his fellow co-hosts: "It's a good news-bad news kind of thing. Good news is we caught it early. Not great news is that it's a little aggressive, so I'm going to be taking some time off to take care of this." Roker's cancer was diagnosed when he was found to have an elevated prostate-specific antigen during a routine physical exam. A repeat test was also high, which led to an MRI of the prostate that showe

The liquid serum assay was cleared for use as a companion diagnostic for olaparib to identify patients with BRCA1/2- and/or ATM-mutated metastatic castration-resistant prostate cancer. The FDA approved another application of Foundation Medicine’s liquid genomic biopsy assay, this time for patients with metastatic castration-resistant prostate cancer (mCRPC), to see if they are candidates for olaparib (Lynparza). The assay, Liquid CDx, was cleared for use as a companion diagnostic for olaparib to identify patients with BRCA1 / 2 - and/or ATM -mutated mCRPC. In September, it was announced that for patients with mCRPC with those alterations, olaparib cut the risk of death by 31% compared with those who received a novel hormonal therapy. Olaparib has already received a category 1 recommendation in guidelines from the National Comprehensive Cancer Network, viewed as the gold standard for payers deciding what new therapies to add to their formulary Liquid CDx is able to evaluate m

DNA strand and Cancer Cell Prostate cancer cells with a deletion of the SUCLA2 gene are linked to treatment resistance and metastasis but can be therapeutically targeted with the compound thymoquinone (TQ), according to a study published in Oncogene . Hormone therapy is a standard treatment for metastatic prostate cancer. Almost half of patients develop resistance to this treatment after two years. Previous studies suggest that a mutation in tumor suppressor gene RB1 is a strong driver of treatment resistance and predicts prognosis in patients. Researchers at Kanazawa University in Japan conducted an analysis of prostate cancer cells and found that cells with a RB1 deletion were also missing SUCLA2, a neighboring gene. After examining prostate cancer tissue, the team found that 11% of cases of advanced disease showed both RB1 and SUCLA2 deletion. Upon further analysis, they discovered that the frequency of SUCLA2 loss significantly aligned with RB1 loss at every disease stage,

Prostate cancer is more common in Black men, and your risk rises as you age. Image Credit: izusek/E+/GettyImages Prostate cancer has a high survival rate overall — in fact, most people who get prostate cancer will survive it — but it's still the second-leading cause of cancer death in people with prostates in the U.S., according to the American Cancer Society. That gives you an idea of how common this type of cancer is. Couple that with the reality that some of the symptoms of prostate cancer can mirror benign prostate issues, especially those associated with normal aging, and it becomes even more important to know the signs of this condition. Read on for more on the basics of prostate cancer, including risk factors, screening recommendations, how it's diagnosed and what treatments are available. What Is Prostate Cancer? Prostate cancer is cancer that originates in the prostate gland, which is only found in people assigned male at birth, according

PROVIDENCE, R.I. (WPRI) — Longtime morning television host and meteorologist Al Roker revealed Friday on the “Today” show that he was battling prostate cancer, and urged others to get yearly screenings in the process. Roker, 66, said he will undergo surgery to have his prostate removed this week. “It’s a good news/bad news kind of thing,” Roker said Friday. “Good news is we caught it early. Not great news is that it’s a little aggressive, so I’m going to be taking some time off to take care of this.” Roker said he publicly revealed his diagnosis to bring awareness to the number of men who are diagnosed with prostate cancer, saying, “it’s a little more common than I think people realize.” According to the American Cancer Society (ACS), prostate cancer is rare in men younger than 40, but the chance of having prostate cancer rises rapidly after age 50. About 6 in 10 cases of prostate cancer are found in men older than 65. “It’s a public service that he did, because he is raising awa

African American and white men with prostate cancer live equally as long if the same care delivery system treats them. (Photo: iStockphoto / NNPA) NNPA NEWSWIRE — @StacyBrownMedia – By Stacy M. Brown, NNPA Newswire Senior National Correspondent -Black men remain more likely to develop more aggressive types of prostate cancer as prostate cancer death rates in African Americans are more than double those of every other racial and ethnic group in the U.S. At a risk rate of 74 percent higher among African American men than non-Hispanic white men, prostate cancer has exacted a deadlier toll on Black men than it does white and all other men of c olor in the United States. According to medical researchers, Black men have the highest risk of developing this cancer and dying from prostate cancer, the most common disease in men and the second-leading cause of cancer-related death in men after lung cancer. Black men remain more likely to develop more aggressive types of prostate cancer as